New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTIDXX, VIVO, EXAS, QDEL, DGX, ABAXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Check below for free stories on IDXX;DGX;EXAS;ABAX;QDEL;VIVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
14:56 EDTEXASExact Sciences volatility elevated
Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.
September 18, 2014
05:44 EDTQDELFlu season could be stronger than expected, says Piper Jaffray
Subscribe for More Information
September 15, 2014
11:28 EDTVIVOMeridian Bioscience announces passing of Executive Chairman William Motto
The Board of Directors of Meridian Bioscience announces the passing of its founder and Executive Chairman of the Board, William J. Motto. In a special meeting held today, September 15, the Board of Directors elected John A. Kraeutler as its Chairman. Kraeutler will now hold the positions of Chairman and CEO.
09:59 EDTABAXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:11 EDTIDXXIDEXX price target lowered to $139 from $148 at Canaccord
Canaccord lowered its price target on IDEXX to $139 from $148 citing near-term multiple compression due to uncertainty following the company's decision to pursue an all-direct sales force. Canaccord maintains its Buy rating on IDEXX.
06:20 EDTABAXAbaxis upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:04 EDTABAXAbaxis upgraded to Buy from Hold at Canaccord
September 9, 2014
07:15 EDTABAXCL King to hold a conference
Subscribe for More Information
September 8, 2014
16:06 EDTDGXQuest Diagnostics: More people testing positive for chikungunya virus in U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use